Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Oxycyte

Other · developed by Tenax Therapeutics

Phase 2 Most advanced trial (none active)
TENX Developer
1 Registered trials

What is Oxycyte?

Oxycyte is a perfluorocarbon. It is studied in traumatic brain injury.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
perfluorocarbon
Drug type
Other
Therapy area
Neurology
Developer
Tenax Therapeutics, Inc. (TENX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
3ZX1Z33VUU

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT00174980 Phase 2 Traumatic Brain Injury Terminated TENX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Traumatic Brain Injury

Follow TENX, the company behind Oxycyte

See TENX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

TENX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.